PROJECT SUIVIMARY (See instmctions): This translational Program Project in lung disease is focused on advancing the field of carbon monoxide (CO) therapeutics in part by examining the impact of low dose CO in the metabolome of lipid mediators (LM), including classic eicosanoids (e.g. prostaglandins and leukotrienes) as well as actions and formation of novel specialized pro-resolving mediators (SPM). In service to achieve this Program Project's goals, this LMLipidomics and Metabolomics Core C will provide centralized, standardized and coordinated lipid mediator (LM) lipidomic profiling, specific mediators and procedures for Projects 1-4. Specifically, Core C will execute newly established procedures for SPM lipidomics and LM pathway metabolomics as a central service required routinely by Projects 1-4. This core will also provide validated eicosanoids, resolvins and related mediators to each of the individual projects as well as maintain quality for their use in each project for assessing CO and its relationship to specific LM and SPM. This Core will set-up, validate and implement new analytical methods as needed for the individual projects. In addition. Core C will characterize the physical properties of synthetic standards and prepare biologically derived authentic LM and SPM. These LM will be validated with biologically generated LM (eicosanoids, prostaglandins and leukotrienes) and novel SPM, including resolvins, protectins and maresins, before distributing to each project. By providing a centralized location for LM lipidomics and pathway metabolomics as standardized services, Core C eliminates costly duplication of instruments and personnel within each project. Prioritization of this Core's service and selection of procedures will be carried out via individual meetings with project investigators and the PI at our regular Program Project meetings in order to achieve optimal use of resources and expertise for this Program Project team in a cost-effective and timely fashion.
Core C will serve Projects 1-4 and play a central role in optimizing resources and standardizing methods for identifying, validating and profiling lipid mediators. By providing these centralized services, this core will facilitate interactions and coordinate key experiments for the investigators in this translational Program Project.
|Harrington, John S; Choi, Augustine M K; Nakahira, Kiichi (2017) Mitochondrial DNA in Sepsis. Curr Opin Crit Care 23:284-290|
|Dalli, Jesmond; Colas, Romain A; Quintana, Carolina et al. (2017) Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes. Crit Care Med 45:58-68|
|Suliman, Hagir B; Kraft, Bryan; Bartz, Raquel et al. (2017) Mitochondrial quality control in alveolar epithelial cells damaged by S. aureus pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 313:L699-L709|
|Finkelsztein, Eli J; Jones, Daniel S; Ma, Kevin C et al. (2017) Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit Care 21:73|
|Ghanta, Sailaja; Tsoyi, Konstantin; Liu, Xiaoli et al. (2017) Mesenchymal Stromal Cells Deficient in Autophagy Proteins Are Susceptible to Oxidative Injury and Mitochondrial Dysfunction. Am J Respir Cell Mol Biol 56:300-309|
|Lasky-Su, Jessica; Dahlin, Amber; Litonjua, Augusto A et al. (2017) Metabolome alterations in severe critical illness and vitamin D status. Crit Care 21:193|
|Putman, Rachel K; Hunninghake, Gary M; Dieffenbach, Paul B et al. (2017) Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 195:138-141|
|Suliman, Hagir B; Keenan, Jeffrey E; Piantadosi, Claude A (2017) Mitochondrial quality-control dysregulation in conditional HO-1-/- mice. JCI Insight 2:e89676|
|Lee, Seonmin; Nakahira, Kiichi; Dalli, Jesmond et al. (2017) NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B4 Synthesis. Am J Respir Crit Care Med 196:713-726|
|Piantadosi, Claude A (2016) Cardioprotective role of S-nitrosylated hemoglobin from rbc. J Clin Invest 126:4402-4403|
Showing the most recent 10 out of 75 publications